Merck KGaA (MKGAF)
| Market Cap | 56.51B |
| Revenue (ttm) | 24.96B |
| Net Income (ttm) | 3.47B |
| Shares Out | n/a |
| EPS (ttm) | 7.98 |
| PE Ratio | 16.29 |
| Forward PE | 13.40 |
| Dividend | 2.50 (1.91%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 700 |
| Average Volume | 475 |
| Open | 128.69 |
| Previous Close | 131.05 |
| Day's Range | 127.03 - 134.87 |
| 52-Week Range | 118.05 - 159.75 |
| Beta | 0.73 |
| RSI | 49.22 |
| Earnings Date | Nov 13, 2025 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography... [Read more]
Full Company ProfileFinancial Performance
In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.
Financial numbers in EUR Financial StatementsNews
Equinix Hosts Merck KGaA's HPC at its Data Center in Germany
EQIX hosts Merck KGaA's new liquid-cooled high-performance computer in Germany, blending private and public cloud to boost scalable, efficient scientific computing.
Valo Health Partners with Merck KGaA in $3B AI Drug Discovery Deal
Valo Health Partners with Merck KGaA in $3B AI Drug Discovery Deal
Merck KGaA inks $3B deal to discover Parkinson’s drugs using AI
Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal
Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially worth over $3 billio...
Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson's Disease and Related Disorders
LEXINGTON, Mass.--(BUSINESS WIRE)--Valo Health announces collaboration with Merck KGaA, Darmstadt, Germany to discover and develop novel treatments for Parkinson's and related disorders.
Merck KGaA (MKKGY) Q3 2025 Earnings Call Transcript
Merck KGaA (OTCPK:MKKGY) Q3 2025 Earnings Call November 13, 2025 8:00 AM ESTCompany ParticipantsFlorian Schraeder - Head of Investor RelationsBelén Garijo...
Merck KGaA 2025 Q3 - Results - Earnings Call Presentation
Merck KGaA (MKGAF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst Market Challenges
Merck KGaA (MKGAF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst Market Challenges
Q3 2025 Merck KGaA Earnings Call Transcript
Q3 2025 Merck KGaA Earnings Call Transcript
Germany’s Merck KGaA Shares Rise After Semiconductor, Pharma Demand Boost Results
Merck KGaA Non-GAAP EPS of €2.32, revenue of €5.32B; updates FY outlook
Merck KGaA's Q3 profit rises, beats market view
Merck KGaA reported on Thursday a slight gain in quarterly operating earnings that beat market expectations, benefiting from legislative changes in South America and the sale of a priority review vouc...
Dr. Rasha Kelej Meets Senegal First Lady at the Merck Foundation Africa Asia Luminary 2025
Business Wire India Merck Foundation, the philanthropic arm of Merck KGaA Germany, recently conducted the 12th Edition of their annual...
Universal Display to buy Oled patent assets from Merck KGaA
MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies Aims to improve researcher access to disease-relevant cell models Strengthens the company’s lea...
Merck KGaA: An AI-Resistant Pharma Play
Merck KGaA (MKGAF) is deeply undervalued, offering a compelling entry point with strong fundamentals and resilience to AI disruption. MKGAF's diversified segments—life science, healthcare (biologics),...
Merck KGaA (MKKGY) Analyst/Investor Day - Slideshow
2025-10-22. The following slide deck was published by Merck KGaA in conjunction with this event.
Merck KGaA Reaches Deal With U.S. To Cut Prices On IVF Drugs
(RTTNews) - Merck KGaA (MKKGY) announced that its U.S. and Canadian healthcare division, EMD Serono, has entered into an agreement with President Donald J. Trump's administration to broaden access to ...
Merck KGaA (MKGAF) Offers Major IVF Discount in New US Deal
Merck KGaA (MKGAF) Offers Major IVF Discount in New US Deal
Trump rolls out his latest deal with a drugmaker. This one stems from his campaign promise to cover all IVF costs.
President Donald Trump on Thursday announced a deal with EMD Serono, a subsidiary of German drugmaker Merck KGaA, that aims to cut the out-of-pocket costs for in vitro fertilization, with the move com...
Trump announces efforts to expand access to IVF drugs
President Donald Trump announced two new efforts to expand availability of in vitro fertilization, the first concrete step from the Trump administration on the expensive, decades-old procedure. It inc...
Trump Announces Deal With Germany's Merck on IVF Costs
President Donald Trump announces a deal with Germany's Merck KGaA to cut the price of some of its fertility medicines in exchange for relief from threatened tariffs. He speaks during a a press confere...
Germany's Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets
The company confirmed its 2025 guidance and is targeting annual organic sales growth in the mid-single-digit percentage range and an expansion in profitability over the medium term.
Germany's Merck tweaks mid-term healthcare unit guidance
German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.
Global Biopreservation Market Set to Surpass USD 7.1 Billion by 2029 | MarketsandMarkets™
Delray Beach, FL,, Oct. 08, 2025 (GLOBE NEWSWIRE) -- formation, and contamination risks threaten sample viability. Ensuring consistent global transportation standards will be a key differentiator for ...